In-Vitro Diagnostics Should Be Eligible For Third-Party Review - Industry
This article was originally published in The Gray Sheet
Executive Summary
FDA should identify more in-vitro diagnostics for inclusion in the agency's "Accredited Persons" third-party premarket review program, DiaSorin VP Regulatory Affairs and Quality Systems, Judith Smith recommended.
You may also be interested in...
DiaSorin Hepatitis B Tests Need Clearer Indication Of "High-Risk" Population
DiaSorin needs to distinguish between specific subgroups of high-risk patient populations in labeling of its ETI Plus line of in vitro diagnostic hepatitis B serological marker assays, FDA's Microbiology Devices Advisory Panel agreed in recommending six assays for approval at a Jan. 20 meeting in Rockville, Maryland.
DiaSorin Hepatitis B Tests Need Clearer Indication Of "High-Risk" Population
DiaSorin needs to distinguish between specific subgroups of high-risk patient populations in labeling of its ETI Plus line of in vitro diagnostic hepatitis B serological marker assays, FDA's Microbiology Devices Advisory Panel agreed in recommending six assays for approval at a Jan. 20 meeting in Rockville, Maryland.
FDA's Third-Party Review Program: Quick Review Times, Low Volume
Third-party 510(k) submissions are gaining FDA clearance at over three times the rate of comparable submissions made directly to the agency, Eric Rechen, a staffer in FDA's Office of Device Evaluation, said.